Which alzheimer's disease psychosis drugs are in Phase 3?

Phase 3 (or later) programs for alzheimer's disease psychosis include Remlifanserin.

What are the next alzheimer's disease psychosis trial readouts?

Upcoming catalysts include Remlifanserin (September to October 2026), ML-007C-MA (2H 2027) and Remlifanserin (January 2028).

4 drug-interventional alzheimer's disease psychosis trials are currently recruiting participants, out of 4 registered interventional trials.

2 compounds from 2 companies are in active clinical development for alzheimer's disease psychosis, including 1 at Phase 3 or beyond.

2Compounds

2Companies

1Phase 3+

3Upcoming readouts

4Trials recruiting

Mechanisms: Small molecule (2)

Pipeline data compiled July 2026 · every fact sourced.

September to October 2026AnticipatedRemlifanserinTopline dataNCT06159673
Topline results from the Phase 2 RADIANT substudy of remlifanserin (ACP-204) 30 mg and 60 mg vs placebo in Alzheimer's disease psychosis (primary endpoint: change from baseline in SAPS-H+D at Week 6), expected September–October 2026. ↗
2H 2027AnticipatedML-007C-MATopline dataNCT06887192
Topline results from the Phase 2 VISTA trial of ML-007C-MA 210/3 mg BID versus placebo in hallucinations and delusions associated with Alzheimer's disease psychosis — primary endpoint change from baseline in NPI-C H+D score at Week 7 — expected in the second half of 2027. ↗
January 2028AnticipatedRemlifanserinRegistry resultsNCT06159673
ClinicalTrials.gov estimated primary completion of the full RADIANT master protocol (NCT06159673), which covers both Phase 3 confirmatory substudies: January 2028 (estimated study completion February 2028). ↗

Compound	Company	Phase	Status	Mechanism
RemlifanserinFDA Fast Track (Alzheimer'S Disease Psychosis; Granted 2026-07-20)	ACADIA Pharmaceuticals Inc.	Phase 3	Active	5-HT2A Inverse agonist
ML-007C-MAFDA Fast Track (Hallucinations And Delusions Associated With Alzheimer'S Disease Psychosis; Granted December 2025, Announced 2026-01-05)	MapLight Therapeutics, Inc.	Phase 2	Recruiting	M1 Agonist

4 drug-interventional alzheimer's disease psychosis trials recruiting now, of 4 registered interventional trials. Browse all on ClinicalTrials.gov →

How many drugs are in development for alzheimer's disease psychosis?: 2 compounds from 2 companies are in active clinical development for alzheimer's disease psychosis, including 1 at Phase 3 or beyond.
Which alzheimer's disease psychosis drugs are in Phase 3?: Phase 3 (or later) programs for alzheimer's disease psychosis include Remlifanserin.
What are the next alzheimer's disease psychosis trial readouts?: Upcoming catalysts include Remlifanserin (September to October 2026), ML-007C-MA (2H 2027) and Remlifanserin (January 2028).
How many clinical trials are recruiting for alzheimer's disease psychosis?: 4 drug-interventional alzheimer's disease psychosis trials are currently recruiting participants, out of 4 registered interventional trials.